Literature DB >> 31647407

An in vitro experimental study of the effect of fosfomycin in combination with amikacin, ciprofloxacin or meropenem on biofilm formation by multidrug-resistant urinary isolates of Escherichia coli.

Sugalya Sugathan1, Jharna Mandal1.   

Abstract

Background. This study was conducted to understand the effect of fosfomycin in combination with amikacin, ciprofloxacin or meropenem on biofilm formation by multidrug-resistant urinary isolates of Escherichia coli.Methods. Fifty urinary tract multidrug-resistant E. coli isolates that were known biofilm producers were studied. The MIC was determined using the agar dilution method for amikacin, ciprofloxacin, meropenem and fosfomycin. The fractional inhibitory concentration was determined for the combination of antibiotics followed by a time-kill assay. A tissue culture plate method was used to study the effect of the combination of antibiotics on biofilm formation.Results. The MICs of the isolates tested ranged from 0.25 to 32 µg ml-1 for fosfomycin, 1 to 1024 µg ml-1 for ciprofloxacin, 4 to 1024 µg ml-1 for amikacin, and 0.25 to 512 µg ml-1 for meropenem. The combination of fosfomycin with meropenem showed 68 % synergy, fosfomycin with amikacin 58 % synergy and fosfomycin with ciprofloxacin 6 % synergy. The combination also reduced the MIC of each antibiotic and none showed an antagonistic effect. Biofilm inhibition was best observed with the combination of fosfomycin with meropenem.Conclusion. The combination of fosfomycin with amikacin and fosfomycin with meropenem yielded a high percentage of synergy alongside an increased capacity to reduce biofilm formation when compared to combination with ciprofloxacin against multidrug-resistant E. coli. Fosfomycin in combination with other classes of antimicrobial agents has potential beneficial effects.

Entities:  

Keywords:  FIC; MDR E.coli; MIC; biofilm; fosfomycin combination

Year:  2019        PMID: 31647407     DOI: 10.1099/jmm.0.001061

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  3 in total

1.  Activity of fosfomycin and amikacin against fosfomycin-heteroresistant Escherichia coli strains in a hollow-fiber infection model.

Authors:  I Portillo-Calderón; M Ortiz-Padilla; B de Gregorio-Iaria; V Merino-Bohorquez; J Blázquez; J Rodríguez-Baño; J M Rodríguez-Martínez; A Pascual; F Docobo-Pérez
Journal:  Antimicrob Agents Chemother       Date:  2021-03-08       Impact factor: 5.191

2.  Efficacy of Fosfomycin against Planktonic and Biofilm-Associated MDR Uropathogenic Escherichia coli Clinical Isolates.

Authors:  Haziel Eleazar Dzib-Baak; Andrés Humberto Uc-Cachón; Angel de Jesús Dzul-Beh; Rey Fernando Rosado-Manzano; Carlos Gracida-Osorno; Gloria María Molina-Salinas
Journal:  Trop Med Infect Dis       Date:  2022-09-08

3.  Use of fosfomycin combination therapy to treat multidrug-resistant urinary tract infection among paediatric surgical patients - a tertiary care centre experience.

Authors:  Shiju K S; Gopichand Pallam; Jharna Mandal; Bibekanand Jindal; Kumaravel S
Journal:  Access Microbiol       Date:  2020-09-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.